Notably, knockdown of VANGL2 or MARCH8 effectively enhanced NLRP3 inflammasome activation in PBMCs from healthy individuals, but not from IBD patients, which strongly suggest a role for VANGL2 in anti-colitis progression via the NLRP3 inflammasome pathway. Here, NLRP3 is linked to colitis.